Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Shire Human Genetic Therapies describes IDS gene therapy

July 12, 2021

YH-34160 leads to potent and sustained body weight loss in DIO mouse model

July 9, 2021

Crinetics Pharmaceuticals synthesizes melanocortin MC2 receptor antagonists

July 9, 2021

Ysopia completes phase I study of Xla-1 for obesity and metabolic diseases

July 8, 2021

AXA-1125 enhances insulin sensitivity in subjects with NAFLD and T2D

July 8, 2021

LY-3305677 is safe and shows body weight-lowering effect in FIH trial

July 8, 2021

Dual GIP/GLP-1 receptor agonist HISHS-2001 displays efficacy in type 2 diabetes model

July 8, 2021

NMPA accepts IND application for TST-002 anti-sclerostin monoclonal antibody

July 7, 2021

SYNB-1934, optimized live bacterial therapeutic for the treatment of phenylketonuria

July 6, 2021

Dose-dependent weight loss seen in first-in-human study of LY-3437943

July 6, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...